title: Hematopoietic, CNS and skeletal muscle stem cells as drug targets: opportunities, progress and challenges.
abstract: Lineage-committed stem and progenitor cells are currently targeted by a handful of medicines, mainly to treat conditions involving the immune and hematopoietic systems. Knowledge of new stem and progenitor cell populations in the body is accumulating at a rapid pace and a new era of targeting resident stem cell populations for therapeutic ends is coming into focus. Small-molecule regulators of body-resident stem and progenitor cell assess are now a reality both in the clinic and as promising new drugs in the development pipeline. This review will explore the current state of the art with an emphasis on emerging concepts and experimental systems in the therapeutic regulation of endogenous stem and progenitor cell populations.
authors.affiliation: GlaxoSmithKline, Research and Development, Muscle Metabolism Research Triangle Park, NC 27709, USA. andrew.n.billin@gsk.com
authors.forename: Andrew
authors.initials: A
authors.lastname: Billin
mesh_terms: D018952:Antigens, CD34 / Q000378:metabolism; D006412:Hematopoietic Stem Cells / Q000166:cytology / Q000187:drug effects*; D006801:Humans; D057026:Induced Pluripotent Stem Cells / Q000166:cytology / Q000187:drug effects; D008024:Ligands; D015398:Signal Transduction; D054852:Small Molecule Libraries / Q000737:chemistry / Q000494:pharmacology*; D013234:Stem Cells / Q000166:cytology / Q000187:drug effects*; D016212:Transforming Growth Factor beta / Q000378:metabolism
chemical_list: D018952:Antigens, CD34; D008024:Ligands; D054852:Small Molecule Libraries; D016212:Transforming Growth Factor beta